

Special Issue

Integrative Genomic Analysis, Big Data Processing and Programming, and Pharmacoinformatics in Biomedicine

Message from the Guest Editor

The development of high-throughput omics and deep sequencing technologies has generated a plethora of data in the public and private omics domains. However, laboratory analysis of these data has failed to meet the urgent clinical needs in cancer, diabetes, cardiovascular diseases, and other chronic diseases. Therefore, innovative computational strategies are needed to address urgent clinical problems. The application of multi-disciplinary strategies that include bioinformatics, genetics, molecular and cell biology, and translational studies would accelerate the proper detection of genetic alterations and determine appropriate disease targets based on next-generation sequencing and genome profiling technologies. This Special Issue welcomes multi-disciplinary original research articles and review papers on integrative genomic analysis, computational genomics, big data processing and programming, cancer genetics, immunobiology, immune checkpoint response prediction, drug target identification and validation, network pharmacology, pharmacogenomics, system biology, and protein–ligand interactions, as well as translational research.

Guest Editor

Dr. Bashir Lawal

Department of Pathology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA

Deadline for manuscript submissions

closed (31 January 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/176277

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).